PainReform (PRFX) Competitors $5.30 -5.86 (-52.51%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PRFX vs. PBM, CWBR, ONCT, GRTX, ERNA, PBLA, REVB, SXTC, KRBP, and CYTOShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Psyence Biomedical (PBM), CohBar (CWBR), Oncternal Therapeutics (ONCT), Galera Therapeutics (GRTX), Eterna Therapeutics (ERNA), Panbela Therapeutics (PBLA), Revelation Biosciences (REVB), China SXT Pharmaceuticals (SXTC), Kiromic BioPharma (KRBP), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Psyence Biomedical CohBar Oncternal Therapeutics Galera Therapeutics Eterna Therapeutics Panbela Therapeutics Revelation Biosciences China SXT Pharmaceuticals Kiromic BioPharma Altamira Therapeutics PainReform (NASDAQ:PRFX) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment. Which has stronger valuation & earnings, PRFX or PBM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$9.34M-$147.33-0.04Psyence BiomedicalN/AN/A-$51.16MN/AN/A Does the media refer more to PRFX or PBM? In the previous week, PainReform had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 7 mentions for PainReform and 6 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 0.43 beat PainReform's score of 0.11 indicating that Psyence Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PainReform 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Psyence Biomedical 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of PRFX or PBM? 37.3% of PainReform shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, PRFX or PBM? PainReform has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500. Does the MarketBeat Community favor PRFX or PBM? PainReform received 3 more outperform votes than Psyence Biomedical when rated by MarketBeat users. CompanyUnderperformOutperformPainReformOutperform Votes375.00% Underperform Votes125.00% Psyence BiomedicalN/AN/A Do analysts rate PRFX or PBM? PainReform presently has a consensus price target of $8.00, indicating a potential upside of 50.94%. Given PainReform's stronger consensus rating and higher possible upside, research analysts clearly believe PainReform is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PRFX or PBM more profitable? Psyence Biomedical's return on equity of 0.00% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A -450.64% -241.33% Psyence Biomedical N/A N/A N/A SummaryPainReform beats Psyence Biomedical on 7 of the 11 factors compared between the two stocks. Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$766,000.00$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.0410.5990.1317.19Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.055.094.784.78Net Income-$9.34M$151.83M$120.31M$225.60M7 Day Performance70.42%-2.14%-1.92%-1.23%1 Month Performance78.45%-4.56%13.65%0.46%1 Year Performance-54.78%8.87%28.34%15.24% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform1.7798 of 5 stars$5.30-52.5%$8.00+50.9%-47.6%$766,000.00N/A-0.044News CoverageGap DownHigh Trading VolumePBMPsyence BiomedicalN/A$1.87+1.1%N/AN/A$1.58MN/A0.00N/ANews CoveragePositive NewsGap UpCWBRCohBarN/A$0.54-0.1%N/A-28.0%$1.57MN/A0.0010ONCTOncternal Therapeutics2.4303 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530Analyst ForecastGRTXGalera TherapeuticsN/A$0.03-5.3%N/A-76.3%$1.55MN/A-0.0530Gap DownERNAEterna TherapeuticsN/A$0.28-2.3%N/A-85.4%$1.53M$598,000.00-0.0310Gap DownHigh Trading VolumePBLAPanbela TherapeuticsN/A$0.31-2.6%$500.00+159,644.4%-98.1%$1.52MN/A0.007Gap DownREVBRevelation Biosciences0.731 of 5 stars$0.35-2.8%N/A-98.3%$1.50MN/A0.0010SXTCChina SXT Pharmaceuticals0.1727 of 5 stars$0.37-5.2%N/A-82.5%$1.48M$1.93M0.0090Positive NewsGap UpKRBPKiromic BioPharmaN/A$0.95flatN/A+162.9%$1.46MN/A-0.1535Gap UpCYTOAltamira Therapeutics1.9288 of 5 stars$0.42-2.5%N/A-90.9%$1.44M$320,000.000.0020News Coverage Related Companies and Tools Related Companies PBM Competitors CWBR Competitors ONCT Competitors GRTX Competitors ERNA Competitors PBLA Competitors REVB Competitors SXTC Competitors KRBP Competitors CYTO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRFX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
